Relapsed Or Refractory Diffuse Large B Cell Lymphoma R R Dlbcl clinical trials

Explore recruiting relapsed or refractory diffuse large b cell lymphoma r r dlbcl clinical trials.

Recruiting relapsed or refractory diffuse large b cell lymphoma r r dlbcl studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Relapsed Or Refractory Diffuse Large B Cell Lymphoma R R Dlbcl trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 3, Single-Arm, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Czechia, Ireland, Hungary, Finland, Denmark, Norway +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 1b/2, Open-Label, Multicenter Study to Evaluate the Safety and Pharmacokinetics of a Modified Tafasitamab IV Dosing Regimen Combined with Lenalidomide (LEN) in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) (MINDway)

Austria, Poland, Italy, Czechia, Spain

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Relapsed Or Refractory Diffuse Large B Cell Lymphoma R R Dlbcl trials by city

Relapsed Or Refractory Diffuse Large B Cell Lymphoma R R Dlbcl clinical trials

Recruiting relapsed or refractory diffuse large b cell lymphoma r r dlbcl studies right now

Enhancing CAR-T Cell Therapy Efficacy in B-cell Lymphoma Via Chidamide and PD-1 Inhibitor Combination.

IOMAB-CAR-T Followed by CAR-T Cell Therapy in R/R DLBCL

A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)

Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCL

A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

Phase I-II Study in CD30 Positive Diffuse Large B-cell Lymphoma Patients Refractory to First Line Chemotherapy or in First Relapse

Also recruiting in Europe

A Phase 3, Single-Arm, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

A Phase 1b/2, Open-Label, Multicenter Study to Evaluate the Safety and Pharmacokinetics of a Modified Tafasitamab IV Dosing Regimen Combined with Lenalidomide (LEN) in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) (MINDway)

Relapsed Or Refractory Diffuse Large B Cell Lymphoma R R Dlbcl trials by city

Other conditions